Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis
作者： C. K. Triantos , N. M. Koukias , V. N. Nikolopoulou , A. K. Burroughs
DOI: 10.1111/J.1365-2036.2011.04822.X
关键词:
摘要: Aliment Pharmacol Ther 2011; 34: 901–910 Summary Background There is no satisfactory medical treatment for patients with primary sclerosing cholangitis. are conflicting data regarding the clinical benefit of high doses ursodeoxycholic acid (UDCA) in cholangitis. Aim To evaluate using meta-analysis, if UDCA (standard or high-dose) useful cholangitis. Methods We searched MEDLINE textwords ‘PSC’, ‘treatment’, ‘UDCA’ and retrieved all abstracts from major Gastroenterology Liver meetings. included randomised trials comparing standard high-dose (>15 mg/kg body weight per day) vs. placebo intervention. End-points: mortality liver transplantation, pruritus, fatigue, cholangiocarcinoma histological progression. Results identified eight comprising 567 patients. Five used three UDCA. was significant difference [OR, 0.6 (95% CI, 0.4–1.4)], pruritus 1.5 0.3–7.2)], fatigue 0.0 0.1–7.7)], 1.7 0.6–5.1)] histology stage progression 0.9 0.34–2.44)]. No differences were found subgroup analyses. Conclusion Neither nor influence favourably
sci-hub.se 参考文章(45)
De Maria N, Van Thiel Dh, Rosenbloom E, Colantoni A, Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. Hepato-gastroenterology. ,vol. 43, pp. 1472- 1479 ,(1996)
E. L. Culver, R. W. Chapman, Systematic review: management options for primary sclerosing cholangitis and its variant forms – IgG4‐associated cholangitis and overlap with autoimmune hepatitis Alimentary Pharmacology & Therapeutics. ,vol. 33, pp. 1273- 1291 ,(2011) , 10.1111/J.1365-2036.2011.04658.X
Goran Poropat, Vanja Giljaca, Davor Stimac, Christian Gluud, Bile acids for primary sclerosing cholangitis. Cochrane Database of Systematic Reviews. ,vol. 2011, pp. 003626-1- 003626-50 ,(2011) , 10.1002/14651858.CD003626.PUB2
J.Mark Farrant, Karen M. Hayllar, Mark L. Wilkinson, John Karani, Bernard C. Portmann, David Westaby, Roger Williams, Natural history and prognostic variables in primary sclerosing cholangitis Gastroenterology. ,vol. 100, pp. 1710- 1717 ,(1991) , 10.1016/0016-5085(91)90673-9
Stephen A. Mitchell, Davinder S. Bansi, Nicholas Hunt, Klaus Von Bergmann, Kenneth A. Fleming, Roger W. Chapman, A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis Gastroenterology. ,vol. 121, pp. 900- 907 ,(2001) , 10.1053/GAST.2001.27965
Jens J W Tischendorf, Hartmut Hecker, Martin Krüger, Michael P Manns, Peter N Meier, Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. The American Journal of Gastroenterology. ,vol. 102, pp. 107- 114 ,(2007) , 10.1111/J.1572-0241.2006.00872.X
Jian Shi, Zhi Li, Xin Zeng, Yong Lin, Wei-Fen Xie, Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials Hepatology Research. ,vol. 39, pp. 865- 873 ,(2009) , 10.1111/J.1872-034X.2009.00527.X
Michael Gluck, Nico R. Cantone, John J. Brandabur, David J. Patterson, James E. Bredfeldt, Richard A. Kozarek, A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis. Journal of Clinical Gastroenterology. ,vol. 42, pp. 1032- 1039 ,(2008) , 10.1097/MCG.0B013E3181646713
Ivo W. Graziadei, Russell H. Wiesner, Paul J. Marotta, Michael K. Porayko, J. Eileen Hay, Michael R. Charlton, John J. Poterucha, Charles B. Rosen, Gregory J. Gores, Nicholas F. LaRusso, Ruud A. F. Krom, Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis Hepatology. ,vol. 30, pp. 1121- 1127 ,(1999) , 10.1002/HEP.510300501
A Benedetti, D Alvaro, C Bassotti, A Gigliozzi, G Ferretti, T La Rosa, A Di Sario, L Baiocchi, A M Jezequel, Cytotoxicity of bile salts against biliary epithelium: A study in isolated bile ductule fragments and isolated perfused rat liver Hepatology. ,vol. 26, pp. 9- 21 ,(1997) , 10.1002/HEP.510260102